The prospect of using bacteriophages as precision weapons against antibiotic-resistant infections faces a fundamental evolutionary trade-off that could work in medicine's favor. When bacteria evolve defenses against therapeutic phages, they often sacrifice other critical capabilities, potentially making them less dangerous pathogens even as they become harder to kill with viral therapy.
Researchers tracked Salmonella enterica as it evolved resistance to phage GRNsp8 over nine days of laboratory coevolution. Three distinct resistance mechanisms emerged: one involving glycosyltransferase modifications that provided partial protection, and two involving mutations to the btuB gene that blocked phage attachment completely. The btuB mutations proved most effective at preventing infection but came with severe penalties. Bacteria lacking functional btuB receptors showed dramatically reduced competitive fitness within 24 hours and required 121 times more cells to kill half of infected mice compared to normal strains.
This evolutionary constraint reflects a deeper biological principle: essential cellular machinery often serves multiple functions simultaneously. The btuB receptor that phages exploit for entry also appears crucial for bacterial virulence and overall fitness. While resistance inevitably emerges, the associated costs suggest phage therapy might succeed not by permanently eliminating pathogens, but by forcing them into weakened states. The challenge lies in developing therapeutic strategies that exploit these fitness trade-offs before bacteria can compensate through additional mutations. Understanding these evolutionary dynamics becomes essential for designing sustainable phage-based treatments that account for both resistance development and the biological costs that constrain it.